Search hospitals > Georgia > Atlanta
Children's Healthcare of Atlanta
Claim this profileAtlanta, Georgia 30322
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
Conducts research for Brain Tumor
Conducts research for Acute Lymphoblastic Leukemia
731 reported clinical trials
60 medical researchers
Summary
Children's Healthcare of Atlanta is a medical facility located in Atlanta, Georgia. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse, Brain Tumor, Acute Lymphoblastic Leukemia and other specialties. Children's Healthcare of Atlanta is involved with conducting 731 clinical trials across 975 conditions. There are 60 research doctors associated with this hospital, such as William T. Cash, Jason Fangusaro, MD, Edmund Waller, MD, and Tobey MacDonald, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderHLA positive
RB1 positive
HLA-A positive
Top PIs
William T. CashChildren's Healthcare of Atlanta - Egleston8 years of reported clinical research
Expert in Neuroblastoma
Expert in Cancer
19 reported clinical trials
34 drugs studied
Jason Fangusaro, MDChildren's Healthcare of Atlanta - Egleston5 years of reported clinical research
Expert in Brain Tumor
Studies Cancer
17 reported clinical trials
28 drugs studied
Edmund Waller, MDEmory University Hospital2 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
15 reported clinical trials
22 drugs studied
Tobey MacDonald, MDChildren's Healthcare of Atlanta1 year of reported clinical research
Studies Brain Tumor
Studies Brain Cancer
11 reported clinical trials
18 drugs studied
Clinical Trials running at Children's Healthcare of Atlanta
Cancer
Acute Lymphoblastic Leukemia
Brain Tumor
Adult T-Cell Leukemia/Lymphoma
Lymphoma
Neuroblastoma
Acute Myeloid Leukemia
Testicular cancer
Acute Leukemia
Solid Tumors
Sirolimus + Chemotherapy
for High-Risk Pediatric Cancers
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Recruiting3 awards Phase 2
Cabozantinib + 13-cis-Retinoic Acid
for Solid Tumors
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Recruiting3 awards Phase 16 criteria
Gamma Delta T Cell Immunotherapy + Chemoimmunotherapy
for Neuroblastoma
This trial tests a new treatment combining existing cancer drugs with special immune cells and a booster drug in children with aggressive neuroblastoma. The goal is to see if this combination can more effectively fight the cancer.
Recruiting3 awards Phase 120 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Healthcare of Atlanta?
Where is Children's Healthcare of Atlanta located?
Who should I call to ask about financial aid or insurance network?
What insurance does Children's Healthcare of Atlanta accept?
What awards or recognition has Children's Healthcare of Atlanta received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.